MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the quarter ending 2026-03-31, JANX had -$506K decrease in cash & cash equivalents over the period. -$12,610K in free cash flow.

Cash Flow Overview

Change in Cash
-$506K
Free Cash flow
-$12,610K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Maturities of short-term investm...
    • Deferred revenue
    • Proceeds from exercise of common...
    • Depreciation
Negative Cash Flow Breakdown
    • Purchases of short-term investme...
    • Accounts receivable
    • Net loss
    • Others

Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Net loss
-24,361 -31,946 -24,313 -57,366
Depreciation
469 468 501 1,060
Stock-based compensation
9,269 9,515 9,044 21,662
Accretion of discounts on investments, net
2,624 3,524 4,623 9,427
Accounts receivable
35,000 --0
Prepaid expenses and other current assets
1,343 227 -449 1,049
Other long-term assets
1,336 -19 -66 -191
Accounts payable
-1,612 1,669 -168 -524
Accrued expenses
-2,030 -4,516 6,179 4,627
Deferred revenue
46,267 0 0 0
Operating lease right-of-use assets and liabilities, net
36 0 -9 11
Net cash used in operating activities
-12,337 -28,542 -12,856 -40,837
Purchases of property and equipment
273 106 93 844
Purchases of short-term investments
112,751 123,277 117,969 463,976
Maturities of short-term investments
121,310 152,926 126,368 125,990
Net cash provided by (used in) investing activities
8,286 29,543 8,306 -338,830
Proceeds from exercise of common stock options and employee stock purchase plan
-2,944 493 1,855
Proceeds from exercise of common stock options
3,545 ---
Proceeds from the issuance of common stock and pre-funded common stock warrants, net of issuance costs
-0 0 -347
Payments of issuance costs
0 ---
Net cash provided by financing activities
3,545 2,944 493 1,508
Net decrease in cash, cash equivalents and restricted cash
-506 3,945 -4,057 -378,159
Cash, cash equivalents and restricted cash - beginning of year
53,150 49,205 431,421 -
Cash, cash equivalents and restricted cash - end of period
52,644 53,150 49,205 -
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Maturities of short-terminvestments$121,310K Proceeds from exercise ofcommon stock options$3,545K Net cash provided by(used in) investing...$8,286K Net cash provided byfinancing activities$3,545K Canceled cashflow$113,024K Net decrease incash, cash...-$506K Canceled cashflow$11,831K Deferred revenue$46,267K Stock-based compensation$9,269K Depreciation$469K Purchases of short-terminvestments$112,751K Purchases of property andequipment$273K Net cash used inoperating activities-$12,337K Canceled cashflow$56,005K Accounts receivable$35,000K Net loss-$24,361K Accretion of discounts oninvestments, net$2,624K Accrued expenses-$2,030K Accounts payable-$1,612K Prepaid expenses andother current assets$1,343K Other long-termassets$1,336K Operating leaseright-of-use assets and...$36K

Janux Therapeutics, Inc. (JANX)

Janux Therapeutics, Inc. (JANX)